Equities Analysts Offer Predictions for MNPR FY2029 Earnings

Monopar Therapeutics Inc. (NASDAQ:MNPR) – Equities researchers at HC Wainwright boosted their FY2029 earnings per share (EPS) estimates for shares of Monopar Therapeutics in a report released on Thursday, August 13th. HC Wainwright analyst A. Maldonado now anticipates that the company will post earnings of $2.44 per share for the year, up from their previous forecast of $2.41. HC Wainwright currently has a “Buy” rating and a $125.00 price target on the stock. The consensus estimate for Monopar Therapeutics’ current full-year earnings is ($2.82) per share. HC Wainwright also issued estimates for Monopar Therapeutics’ FY2030 earnings at $6.77 EPS.

A number of other research firms have also issued reports on MNPR. Wall Street Zen upgraded shares of Monopar Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Zacks Research raised shares of Monopar Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Monday, July 13th. Barclays reaffirmed an “overweight” rating and issued a $128.00 target price (up from $125.00) on shares of Monopar Therapeutics in a research note on Thursday. Piper Sandler set a $105.00 price objective on Monopar Therapeutics in a report on Tuesday, June 2nd. Finally, UBS Group set a $125.00 target price on Monopar Therapeutics in a research report on Thursday, July 23rd. Three investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $117.42.

Monopar Therapeutics Stock Down 3.9%

MNPR opened at $110.41 on Friday. The firm has a market cap of $739.75 million, a P/E ratio of -50.88 and a beta of 1.47. The business’s fifty day simple moving average is $95.04 and its 200 day simple moving average is $71.23. Monopar Therapeutics has a 52 week low of $29.18 and a 52 week high of $124.82.

Monopar Therapeutics (NASDAQ:MNPR) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.62) earnings per share for the quarter, topping the consensus estimate of ($0.64) by $0.02.

Hedge Funds Weigh In On Monopar Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MNPR. Wellington Management Group LLP purchased a new stake in shares of Monopar Therapeutics during the third quarter worth about $18,904,000. Siren L.L.C. acquired a new stake in Monopar Therapeutics during the 4th quarter valued at approximately $13,863,000. Deerfield Management Company L.P. acquired a new stake in Monopar Therapeutics during the 3rd quarter valued at approximately $13,048,000. RA Capital Management L.P. increased its holdings in Monopar Therapeutics by 30.5% during the 4th quarter. RA Capital Management L.P. now owns 667,207 shares of the company’s stock worth $43,569,000 after purchasing an additional 156,000 shares during the last quarter. Finally, TCG Crossover Management LLC purchased a new stake in Monopar Therapeutics during the 3rd quarter worth approximately $12,496,000. 1.83% of the stock is owned by hedge funds and other institutional investors.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.